INVO Fertility, Inc. (IVF) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. INVO Fertility, Inc. (formerly NAYA Therapeutics) is a healthcare services and technology company focused on the fertility marketplace. The company operates fertility clinics (including the Wisconsin Fertility Institute and INVO Centers in Atlanta and Birmingham) and sells the INVOcell medical device. In Q2 2025, the company divested 80.1% of its NAYA Therapeutics subsidiary to refocus exclusively on fertility, resulting in the reclassification of NAYA operations as discontinued.
Key Financial Metrics (Nine Months Ended Sept 30, 2025)
- Revenue: $5.26 million (Continuing Operations), up 8.5% from $4.85 million in the prior year period.
- Net Loss: $25.33 million total, driven by a $16.45 million loss from discontinued operations (NAYA) and a $7.35 million loss from continuing operations.
- Operating Loss (Continuing): $5.83 million.
- Cash and Cash Equivalents: $355,891 as of September 30, 2025 (down from $619,520 at year-end 2024).
- Working Capital: Negative $8.11 million (Current Assets: $1.14M; Current Liabilities: $9.24M).
- Debt: Total notes payable (net) of approximately $2.0 million, including related party notes and convertible debentures.
- Stockholders' Equity: $5.85 million.
Material Changes vs. Prior Period
- Discontinued Operations: The most significant change is the divestiture of NAYA Therapeutics. This resulted in a $16.45 million loss from discontinued operations and a $1.53 million loss on disposal, which are excluded from continuing operations analysis.
- Revenue Growth: Clinic revenue increased to $5.18 million (9 months) due to organic growth at the Wisconsin and Atlanta clinics.
- Impairment Loss: A non-cash impairment loss of $1.40 million was recognized on the Wisconsin clinic's non-competition agreement following a settlement with Dr. Pritts.
- Debt Restructuring: Significant debt extinguishment losses of $1.57 million were recorded due to the conversion of convertible debentures into Series C-2 Preferred Stock.
- Settlement Gain: A gain of $0.71 million was recognized related to the settlement of the WFI acquisition dispute.
Guidance, Outlook, Risks, and Unusual Items
- Liquidity and Going Concern: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern for at least one year. Cash on hand ($0.36M) is insufficient to fund operations without additional financing.
- Capital Raising: The company raised $8.75 million in a January 2025 public offering and $2.15 million from preferred stock sales. Proceeds were used to redeem $4.0 million of Series C-2 Preferred Stock and repay debt.
- Strategic Focus: Management plans to grow the Wisconsin Fertility Institute and pursue acquisitions of profitable U.S.-based IVF clinics.
- Legal Settlement: A $5.0 million settlement agreement was executed with Dr. Elizabeth Pritts regarding the WFI acquisition. Payments are scheduled through December 2026, with 25% of gross funding proceeds above $2.0 million in any six-month period dedicated to accelerating payments.
- Internal Controls: The company disclosed that disclosure controls and procedures were not effective as of September 30, 2025, due to material weaknesses in internal control over financial reporting.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the $0.36M cash balance and $7.0M operating cash burn over nine months.
- Settlement Obligations: Confirm the schedule and funding source for the remaining $4.475 million owed to Dr. Pritts under the settlement agreement.
- Debt Conversion Terms: Review the dilution impact of the Series C-2 Preferred Stock, which has an "Additional Investment Right" allowing a major holder to purchase up to $10M more at potentially discounted conversion prices.
- Internal Control Remediation: Assess the plan to remediate the material weaknesses in financial reporting controls.
- Discontinued Operations: Ensure financial analysis excludes the $18M loss from NAYA Therapeutics to accurately assess the core fertility business performance.